Yabao Pharmaceutical Group Co Ltd (600351.SS)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Yabao Pharmaceutical Group sees FY 2017 net profit to up 60 pct to 80 pct
- China stocks rise, led by financials and property firms
- Shanghai stock market edges up, but blue-chip index down
- BRIEF-Yabao Pharma Sees 2017 Net Profit Up 788-818 Pct On Rising Sales Of High Margin Products
- BRIEF-Yabao Pharmaceutical Group halts plan to set up private bank